Naloxone Access: Answering Questions
Virtual Public Meeting 
Tuesday, March 29, 2022
12:30 – 3 PM Eastern Time

Drug overdose persists as a major public health issue in the United States, killing 100,000 people from May 2020-April 2021. That’s the highest recorded number of overdose deaths in a 12-month period in the US according to the CDC. Synthetic opioids, such as fentanyl, were the primary driver of the increase in overdose deaths.

The Reagan-Udall Foundation for the FDA, in collaboration with the U.S. Food and Drug Administration, hosted a virtual public meeting to explore some of the most frequently asked questions about access to naloxone, a drug used to reverse opioid overdoses. Harm reduction specialists, physicians, pharmacists, and regulators shared their experiences in addressing the availability of this life-saving medication for heroin, fentanyl, and prescription opioid overdose.

 

Watch the full event below. 

 

Naloxone Access Transcript  Read the transcript                                      slide thumbnail View slide deck

Agenda

Moderated by Susan C. Winckler, RPh, Esq., Reagan-Udall Foundation for the FDA 

12:30 pm Welcome
12:35 pm Opening Remarks 
Patrizia Cavazzoni, MD, U.S. Food and Drug Administration
12:40 pm

Current Landscape of Naloxone Access
Panelists:

  • Josh Bolin, National Association of Boards of Pharmacy
  • Marta Sokolowska, PhD, U.S. Food and Drug Administration
  • Nabarun Dasgupta, PhD, MPH, University of North Carolina
  • Bobby Mukkamala, MD, American Medical Association
  • Jeffrey Bratberg, PharmD, The University of Rhode Island
2 pm Public Comment
Members of the public may register ahead of time to provide two minutes of oral comments. (Limited to 30 speakers)
3 pm Adjourn

Download agenda

Speaker Biographies